(Reuters) - The Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said...
March 7 (Reuters) - The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.
The FDA requests that Regeneron ( REGN ) and Sanofi ( SNY ) assess potential neurocognitive side effects of their late stage cholesterol drug alirocumab , a PCSK9 inhibitor
Pharmaceuticals ( ISIS ), Gilead ( GILD ), Celgene ( CELG ), Regeneron ( REGN ), Biogen Idec ( BIIB ), Perrigo ( PRGO ), WhiteWave ( WWAV ..... Pharmaceuticals ( ISIS ), Biogen Idec ( BIIB ), Regeneron ( REGN ), Gilead ( GILD ), Celgene ( CELG ) 3. Consumer Frugality
Bayer ( OTCPK:BAYRY ) has filed for Japanese approval of Regeneron's ( REGN ) Eylea therapy for treating patients with diabetic macular edema , the companies have said. Bayer has the rights to sell Eyelea
Bayer believes that Xarelto (blood thinner) and Eylea (eye), which is developed by Regeneron ( REGN ), will hit peak revenues in 5-6 years . Bayer holds the license to sell Eylea outside the U.S. Bayer has increased its combined
Grill ( CMG ), Facebook ( FB ), Google ( GOOG ), Michael Kors ( KORS ), Netflix ( NFLX ), Priceline ( PCLN ), Regeneron ( REGN ), SolarCity ( SCTY ), Stratasys ( SSYS ), Tesla ( TSLA ), Twitter ( TWTR ), Under Armour ( UA ), Workday ( WDAY ), Yelp
The FDA has accepted Regeneron's ( REGN +3.3% ) application to expand the use of its Eylea therapy to treat Macular Edema Following Branch Retinal Vein Occlusion
By Dr. Paul Nunzio De Santis, Pharm.D : Assessing the Long and Short View of pSivida Corp. Company Overview pSivida Corp. ( PSDV ) is not a proof-of-concept stage biopharmaceutical company, but is a developer of a proven, sustained release drug delivery system. pSivida already has two approved ...
Regeneron's ( REGN ) 7.4% gain topped today's S&P leader board following Q4 earnings ..... S. sales of the sight-saving drug rose 46% Y/Y to $402M, and REGN forecasts U.S. sales to reach $1.7B-$1.8B this year as it expects